Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$37.67

-0.11 (-0.29%)

07:30
11/06/18
11/06
07:30
11/06/18
07:30

Alkermes price target lowered to $41 from $46 at Cantor Fitzgerald

Cantor Fitzgerald analyst William Tanner lowered his price target for Alkermes to $41 from $46 and reiterates a Neutral rating on the shares. The FDA advisory panel view of the ALKS 5461 NDA is a "major setback" not only for the drug but also to the ability of Alkermes to convince investors that the company can develop proprietary therapies of meaningful commercial potential, Tanner tells investors in a research note. He now believes the upcoming ALKS-3831 Enlighten-2 data release "looms larger" after the ALKS 5461 panel decision.

  • 12

    Nov

  • 31

    Jan

ALKS Alkermes
$37.67

-0.11 (-0.29%)

10/30/18
GSCO
10/30/18
NO CHANGE
Target $49
GSCO
Neutral
FDA now more likely to request another trial from Alkermes, says Goldman Sachs
Goldman Sachs analyst Terence Flynn says his first read of the FDA briefing documents on ALKS 5461 is in line with his expectations "as it appears that the FDA has a number of questions regarding the existing data/analysis." The analyst now sees a higher likelihood that the FDA requests a confirmatory Phase 3 trial prior to approval of the depression drug. The briefing documents indicate that the review of statistical evidence will be based solely on the one positive Phase 3 study, as in the committee's view study 202 was considered "proof of concept" rather than "proof of efficacy," Flynn tells investors in a research note. He adds, though, that removing ALKS 5461 from his model takes his implied valuation for the company to $41 per share, all else being equal. Alkermes is morning trading is down 37c to $40.00. Flynn keeps a Neutral rating on the shares with a $49 price target.
11/02/18
STFL
11/02/18
NO CHANGE
Target $40
STFL
Hold
Alkermes price target lowered to $40 from $44 at Stifel
Stifel analyst Paul Matteis removed any near-term credit for ALKS5461 from his model after a 3-20 advisory committee vote against substantial evidence of effectiveness in major depressive disorder. The advisory committee meeting firmed his view that the drug will not be approved during this review cycle, said Matteis, who keeps a Hold rating on Alkermes shares and lowered his price target to $40 from $44.
11/02/18
JPMS
11/02/18
NO CHANGE
JPMS
Overweight
Alkermes panel vote puts more pressure on ALKS 3831, says JPMorgan
The "decidedly negative" FDA panel vote yesterday for ALKS 5461, while unsurprising following the briefing documents, put "significantly more pressure" on the pending ALKS 3831 Phase 3 readout in schizophrenia later this quarter, JPMorgan analyst Cory Kasimov tells investors in a research note titled "ALKS Uphill Climb Fails to Reach the Summit." The analyst, however, believes yesterday's panel vote was broadly viewed as a "very high risk shot on goal" and notes he completely removed ALKS 5461 from his model last year. Nevertheless, "this is clearly not a great way to kick off a catalyst rich period for the company," says Kasimov. He has an Overweight rating on Alkermes and continues to estimate the fair value of the company's base business at $33 per share.
11/05/18
PIPR
11/05/18
INITIATION
Target $40
PIPR
Neutral
Alkermes initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Danielle Brill started Alkermes (ALKS) with a Neutral rating and $40 price target. The analyst says that while the shares are trading near 52-week lows, she struggles "to find something that will turn things around." She expects a positive data readout in Q4 from oral schizophrenia drug ALKS 3831, but believes this opportunity is already priced into shares. Proprietary pipeline sales will offset declining license and manufacturing agreement revenue, but Alkermes' overall annual growth "appears modest" at around 8%, Brill tells investors in a research note. She would start to get more constructive on the shares with signs of more robust revenue growth, such as indications that BIIB098 will be a big product for Biogen (BIIB), and/or Aristada successfully demonstrating superiority over Invega Sustenna in the ongoing head-to-head trial.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

12:40
11/16/18
11/16
12:40
11/16/18
12:40
General news
Breaking General news story on S&P 500, SPDR S&P 500 ETF Trust »

Trump says would like to…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

12:40
11/16/18
11/16
12:40
11/16/18
12:40
General news
Breaking General news story on S&P 500, SPDR S&P 500 ETF Trust »

Trump says does not want…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$272.55

-0.29 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$20.54

-0.53 (-2.52%)

12:40
11/16/18
11/16
12:40
11/16/18
12:40
Options
4K Jun 22.5 calls on iQiyi trade $3.40 »

4K Jun 22.5 calls on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$138.09

-5.77 (-4.01%)

12:38
11/16/18
11/16
12:38
11/16/18
12:38
Hot Stocks
Definers says not hired by Facebook for opposition research »

Definers Public Affairs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

LYB

LyondellBasell

$94.38

0.95 (1.02%)

, BAK

Braskem

$27.66

0.56 (2.07%)

12:30
11/16/18
11/16
12:30
11/16/18
12:30
Periodicals
LyondellBasell close to presenting binding offer for Braskem, Reuters says »

LyondellBasell (LYB) is…

LYB

LyondellBasell

$94.38

0.95 (1.02%)

BAK

Braskem

$27.66

0.56 (2.07%)

PBR

Petrobras

$14.87

0.32 (2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$68.91

0.24 (0.35%)

12:30
11/16/18
11/16
12:30
11/16/18
12:30
Options
Call buying in Cognizant Tech as the company hosts an Investor Day Friday »

Call buying in Cognizant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

  • 26

    Nov

  • 02

    Dec

BAK

Braskem

$27.74

0.64 (2.36%)

, LYB

LyondellBasell

$94.44

1.01 (1.08%)

12:26
11/16/18
11/16
12:26
11/16/18
12:26
Hot Stocks
Breaking Hot Stocks news story on Braskem, LyondellBasell »

Braskem up 54c to $27.68…

BAK

Braskem

$27.74

0.64 (2.36%)

LYB

LyondellBasell

$94.44

1.01 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

12:25
11/16/18
11/16
12:25
11/16/18
12:25
Periodicals
Airbus, Dassault plan to submit bid for early work on new jet, Reuters says »

Airbus and Dassault…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
11/16/18
11/16
12:25
11/16/18
12:25
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

LYB

LyondellBasell

$94.48

1.05 (1.12%)

12:24
11/16/18
11/16
12:24
11/16/18
12:24
Periodicals
LyondellBasell close to presenting binding offer for Braskem, Reuters says »

LyondellBasell is close…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$54.66

-0.04 (-0.07%)

12:20
11/16/18
11/16
12:20
11/16/18
12:20
Options
Bearish option flow in Materials Sector ETF »

Bearish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:20
11/16/18
11/16
12:20
11/16/18
12:20
General news
More from Evans: the short-term policy rate is the first instrument »

More from Evans: the…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/16/18
11/16
12:17
11/16/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/16/18
11/16
12:16
11/16/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$157.34

-2.06 (-1.29%)

12:09
11/16/18
11/16
12:09
11/16/18
12:09
Periodicals
Allergan wins ruling over generic Saphris, Bloomberg reports »

Allergan's Forest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$166.50

-36.15 (-17.84%)

, AMAT

Applied Materials

$34.39

-0.64 (-1.83%)

12:05
11/16/18
11/16
12:05
11/16/18
12:05
OnTheFly
Fly Intel: Wall Street's top stories at midday »

Stocks opened sharply…

NVDA

Nvidia

$166.50

-36.15 (-17.84%)

AMAT

Applied Materials

$34.39

-0.64 (-1.83%)

SONO

Sonos

$15.21

1.07 (7.57%)

PCG

PG&E

$23.93

6.16 (34.67%)

TRN

Trinity Industries

$22.61

0.87 (4.00%)

ACHC

Acadia

$30.63

-7.22 (-19.08%)

JWN

Nordstrom

$50.83

-8.14 (-13.80%)

WSM

Williams-Sonoma

$53.26

-7.34 (-12.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 26

    Nov

  • 10

    Dec

JWN

Nordstrom

$51.02

-7.95 (-13.48%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Hot Stocks
Nordstrom falls -13.5% »

Nordstrom is down -13.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAIR

Wesco Aircraft

$9.54

-1.705 (-15.17%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Hot Stocks
Wesco Aircraft falls -15.2% »

Wesco Aircraft is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$24.00

6.23 (35.06%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Hot Stocks
Fitch downgrades PG&E Corp and utility sub to 'BBB-' on negative watch »

Fitch Ratings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$3.98

-0.735 (-15.59%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Hot Stocks
VelocityShares 3x Inv Natural Gas ETN falls -15.3% »

VelocityShares 3x Inv…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XME

SPDR S&P Metals & Mining

$31.10

0.15 (0.48%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Options
Bullish option flow in SPDR Metals and Mining Fund »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$130.80

20.3 (18.37%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Hot Stocks
VelocityShares 3x Long Natural Gas ETN rises 18.4% »

VelocityShares 3x Long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGVC

Natural Grocers

$20.28

3.62 (21.73%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Hot Stocks
Natural Grocers rises 21.7% »

Natural Grocers is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$24.00

6.23 (35.06%)

12:00
11/16/18
11/16
12:00
11/16/18
12:00
Hot Stocks
PG&E rises 35.3% »

PG&E is up 35.3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$26.27

-0.13 (-0.49%)

, WYNN

Wynn Resorts

$105.87

-0.48 (-0.45%)

11:55
11/16/18
11/16
11:55
11/16/18
11:55
Hot Stocks
NJ reports October gaming revenue up 15.8% to $239.1M »

New Jersey's…

MGM

MGM Resorts

$26.27

-0.13 (-0.49%)

WYNN

Wynn Resorts

$105.87

-0.48 (-0.45%)

LVS

Las Vegas Sands

$53.24

-0.5 (-0.93%)

CZR

Caesars

$8.38

-0.115 (-1.35%)

PENN

Penn National

$21.28

-0.06 (-0.28%)

BYD

Boyd Gaming

$24.86

-0.31 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.